ArticleAging2018
GC-MS-based metabolomics approach to diagnose depression in hepatitis B virus-infected patients with middle or old age.
Article in Aging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- A Systematic Review of Circulatory microRNAs in Major Depressive Disorder: Potential Biomarkers for Disease Prognosis.International journal of molecular sciences · 2022Pooled it
- Association between resolved hepatitis B virus infection and depression in American adults : a cross-sectional study.Scientific reports · 2025Article
- From Complexity to Clarity: Expanding Metabolome Coverage With Innovative Analytical Strategies.Journal of separation science · 2025Review
- Phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1 is a diagnostic and prognostic biomarker for hepatocellular carcinoma.World journal of clinical cases · 2020Article
- Age-specific differential changes on gut microbiota composition in patients with major depressive disorder.Aging · 2020Article
- Dual Metabolomic Platforms Identified a Novel Urinary Metabolite Signature for Hepatitis B Virus-Infected Patients with Depression.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020Article
- Age-specific urinary metabolite signatures and functions in patients with major depressive disorder.Aging · 2019Article
- Article
- Efficacy of ginkgo biloba extract as augmentation of venlafaxine in treating post-stroke depression.Neuropsychiatric disease and treatment · 2019Article
- Urinary biomarkers for diagnosing poststroke depression in patients with type 2 diabetes mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2019Article
- Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression is concomitantly presented in hepatitis B virus (HBV)-infected patients (HB). However, there is still no objective method to diagnose HBV-infected patients with depression (dHB). Therefore, in this study, a gas chromatography-mass spectrometry (GC-MS)-based metabolomic approach was employed to profile urine samples from 59 dHB and 52 HB (the training set) in order to identify urinary metabolite biomarkers for dHB. Then, 41 dHB and 35 HB (the testing set) were used to independently validate the diagnostic generalizability of these biomarkers. In total, 13 differential metabolites responsible for the discrimination between dHB and HB were identified. These differential urinary metabolites belonged mainly to Lipid metabolism and Amino acid metabolism. A panel consisting of six urinary metabolite biomarkers (ethanolamine, azelaic acid, histidine, threitol, 2,4-dihydroxypyrimidine and levulinic acid) was identified. This panel was capable of distinguishing dHB from HB with an area under the receiver operating characteristic curve (AUC) of 0.986 in the training set. Moreover, this panel could classify blinded samples from the testing set with an AUC of 0.933. These findings indicated that the GC-MS-based metabolomics approach could be a useful tool in the clinical diagnosis of dHB, and the identified biomarkers were helpful for future developing an objective diagnostic method for dHB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.